[Media Coverage] WIRED: “Reframing Futures of Global Health | Engineering Immunity” (Interview with Wataru Akahata)
An interview with Wataru Akahata, CEO of VLP Therapeutics (VLPT) and VLPT Japan, has been featured in the latest issue of WIRED magazine and on its online edition. "Vaccine development is incredibly hard, but once
[News Release] VLP Therapeutics Japan initiates Phase 1 clinical trial of T-cell inducing COVID-19 vaccine: advancing the development of a universal vaccine against multiple SARS-CoV-2 variants
VLP Therapeutics Japan, Inc. (VLPT Japan), a Tokyo-based biotech company, announced on March 31 the initiation of a Phase 1 clinical trial in Japan for its COVID-19 vaccine (VLPCOV-U-01). VLPCOV-U-01 is a novel T-cell inducing
[News Release] VLP Therapeutics Japan reports safety, immunogenicity, and optimal dosing of VLPCOV-02, a SARS-CoV-2 saRNA vaccine with modified 5-methylcytosine base [iScience]
VLP Therapeutics Japan, Inc. (VLPT Japan) researchers and their colleagues at the National Institutes of Biomedical Innovation, Health and Nutrition (NIBN) in Japan published a paper in iScience online reporting safety, immunogenicity, and optimal dosing
[News Release] VLP Therapeutics awarded US$ 2.8 million grant to develop novel malaria vaccines that improve protection, reduce costs, expand equitable access
Maryland, US-based biotech company VLP Therapeutics, Inc. (VLPT) announced today that it has been awarded a two-year grant of over US$ 2.8 million (about JPY 433 million) from the Gates Foundation to develop next-gen multi-stage
Our Platform Technologies
Surface Antigen Display
i-αVLP Platform
Cancer Vaccine
Malaria Vaccine
Interior Gene Delivery
Replicon Platform
Cancer Therapy
Native Virus Modification
Native Virus Vaccines
Dengue Vaccine
Vaccines are one of the most important inventions in the past centuries. The successful vaccines save millions of lives by eradicating the epidemic and pandemic diseases. I left the research field and formed VLP Therapeutics because I am committed to developing the next generation vaccine technology to treat the diseases that currently lack effective treatment. We believe that our i-αVLP vaccine technology has a potential to create a breakthrough treatments and make significant contributions to the improvement of global public health.